Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: A double-blinded, placebo-controlled crossover trial
Autore:
Wolfe, DL; Hayes, KC; Hsieh, JTC; Potter, PJ;
Indirizzi:
Univ Western Ontario, Dept Phys Med & Rehabil, London, ON N6A 3K7, Canada Univ Western Ontario London ON Canada N6A 3K7 London, ON N6A 3K7, Canada Lawson Res Inst, Div Rehabil & Geriatr Med, London, ON, Canada Lawson Res Inst London ON Canada habil & Geriatr Med, London, ON, Canada St Josephs Hlth Care London, London, England St Josephs Hlth Care London London England Care London, London, England
Titolo Testata:
JOURNAL OF NEUROTRAUMA
fascicolo: 8, volume: 18, anno: 2001,
pagine: 757 - 771
SICI:
0897-7151(200108)18:8<757:EO4OME>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSCRANIAL MAGNETIC STIMULATION; MAMMALIAN NERVE-FIBERS; CA1 PYRAMIDAL NEURONS; MULTIPLE-SCLEROSIS; NEUROMUSCULAR-TRANSMISSION; SYNCHRONOUS POTENTIALS; EPILEPTIFORM ACTIVITY; AXONAL CONDUCTION; HUMAN-BRAIN; LONG-TERM;
Keywords:
4-aminopyridine; cortical excitability; electrophysiology; human; motor evoked potentials; spinal cord injury; transcranial magnetic stimulation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
53
Recensione:
Indirizzi per estratti:
Indirizzo: Wolfe, DL Univ Western Ontario, Dept Phys Med & Rehabil, London, ON N6A 3K7, Canada Univ Western Ontario London ON Canada N6A 3K7 N N6A 3K7, Canada
Citazione:
D.L. Wolfe et al., "Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: A double-blinded, placebo-controlled crossover trial", J NEUROTRAU, 18(8), 2001, pp. 757-771

Abstract

4-Aminopyridine (4-AP) is a potassium (K+) channel blocking agent that hasbeen shown to reduce the latency and increase the amplitude of motor evoked potentials (MEPs) elicited with transcranial magnetic stimulation (TMS) in patients with chronic spinal cord injury (SCI). These effects on MEPs arethought to reflect enhanced conduction in long tract axons brought about by overcoming conduction deficits due to focal demyelination and/or by enhancing neuroneuronal transmission at one or more sites of the neuraxis. The present study was designed to obtain further evidence of reduced central motor conduction time (CMCT) and to determine whether MEPs could be recorded from paretic muscles in which they were not normally elicited. MEPs were elicited with TMS being delivered to subjects (n = 25) pre- and post-administration of 4-AP (10 mg capsule) or placebo. The principal finding was that 4-AP lowered the stimulation threshold, increased the amplitude and reduced the latency of MEPs in all muscles tested, including those that were unimpaired, but did not alter measures of the peripheral nervous system (i.e., M-wave, H-reflex, F-wave). These 4-AP-induced changes in MEPs were significantly greater than those seen with placebo (p < 0.05). The primary implicationof these results is that a low dose of 4-AP (immediate-release formulation) appears to improve the impaired central motor conduction of some patientswith incomplete SCI. This is most likely attributable to overcoming conduction deficits at the site of injury but may also involve an increase in cortical excitability.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 08:09:06